News
FDA again turns back Capricor Duchenne cell therapy
BioPharma Dive · By Gwendolyn Wu ·
The Brief
- The FDA again rejected Capricor's Duchenne cell therapy, deramiocel.
- In an unusual statement, the FDA accused Capricor of "serious data integrity violations" that compromised its study findings.
- This is the second rejection of deramiocel since 2025.
Why it matters
The case shows that regulators can reject a therapy over data integrity problems that undermine a study's findings, so the reliability of trial data is decisive for approval.
Who’s affected
- researchers and clinicians working on Duchenne muscular dystrophy
- biotech and drug developers
- #duchenne
- #cell therapy
- #fda
- #data integrity
- #clinical trials
- #drug regulation
In an unusual statement, the FDA accused Capricor of “serious data integrity violations” that compromised its study findings and led to deramiocel’s second rejection since 2025.